Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Pharvaris ( (PHVS) ) has issued an update.
Pharvaris reported first-quarter 2026 results on May 12, 2026, highlighting continued investment in late-stage trials of its oral angioedema drug deucrictibant and preparations for commercialization. The company closed a $132 million underwritten equity offering and, together with €247 million in cash at March 31, 2026, now expects its funding runway to extend into 2028.
Operationally, Pharvaris is on track to file a U.S. NDA in the first half of 2026 for deucrictibant immediate-release capsules for on-demand treatment of hereditary angioedema attacks and plans to report pivotal Phase 3 CHAPTER-3 topline data for the extended-release prophylactic tablet in the third quarter of 2026. Enrollment is progressing in both the CHAPTER-4 extension study in HAE and the CREAATE Phase 3 study in acquired angioedema, while quarterly R&D spending held roughly flat year on year and the net loss narrowed, underscoring disciplined spending as the company builds commercial infrastructure.
The most recent analyst rating on (PHVS) stock is a Hold with a $31.00 price target. To see the full list of analyst forecasts on Pharvaris stock, see the PHVS Stock Forecast page.
Spark’s Take on PHVS Stock
According to Spark, TipRanks’ AI Analyst, PHVS is a Neutral.
The score is primarily held back by weak financial performance driven by ongoing losses and increasing cash burn, despite a conservatively levered balance sheet. Technicals are supportive with the stock trading above major moving averages and positive momentum, while valuation remains challenged due to a negative P/E and no dividend yield provided.
To see Spark’s full report on PHVS stock, click here.
More about Pharvaris
Pharvaris is a late-stage biopharmaceutical company focused on developing novel, oral bradykinin B2 receptor antagonists for bradykinin-mediated conditions, including hereditary and acquired angioedema. Its lead candidate, deucrictibant, is being advanced in both extended-release and immediate-release oral formulations aimed at providing injectable-like efficacy with the convenience of oral dosing.
Average Trading Volume: 236,507
Technical Sentiment Signal: Buy
Current Market Cap: $1.97B
See more insights into PHVS stock on TipRanks’ Stock Analysis page.